Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390874 | 1.00 | CYP1A2 (0.61) | CYP1A2BACE1CYP2C19HTTKDM4E | |
| SCHEMBL935575 | 0.84 | CYP1A2 (0.63) | CYP1A2BACE1KDM4ELMNAPOLB | |
| Iodomethane SCHEMBL28083725 | 0.81 | CYP1A2 (0.59) | CYP1A2BACE1KDM4ELMNAPOLB | |
| SCHEMBL10259445 | 0.78 | CYP1A2 (0.68) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL951793 | 0.76 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL30081469 | 0.76 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL28417141 | 0.76 | BACE1 (0.61) | CYP1A2BACE1CYP2C19HTTKDM4E | |
| SCHEMBL31261751 | 0.76 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL28184246 | 0.75 | BACE1 (0.60) | CYP1A2BACE1CYP2C19HTTKDM4E | |
| SCHEMBL9217980 | 0.75 | CYP1A2 (0.65) | CYP1A2HTTKDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116376166-A | Antistatic polypropylene resin and preparation method thereof | 马德义 | 2023-07-04 | — | — | CN | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-4918081-A | Quinoline derivatives and use thereof as antagonists of leukotriene d4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-17 | — | — | US | disclosed |
| WO-1989012629-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
| EP-0219308-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
| EP-0219307-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | CYP1A2 3824/4885BACE1 4323/4885CYP2C19 3496/4885 |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885BACE1 3865/4885CYP2C19 1110/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | CYP1A2 4269/4885BACE1 2394/4885CYP2C19 4111/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CYP1A2 439/4885BACE1 3865/4885CYP2C19 1110/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | CYP1A2 4269/4885BACE1 2394/4885CYP2C19 4111/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CYP1A2 3502/4885BACE1 4367/4885CYP2C19 3083/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885BACE1 3865/4885CYP2C19 1110/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | CYP1A2 15/4885BACE1 935/4885CYP2C19 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.